PolycapTM is indicated for Secondary Prevention of CVD as it contains following 5 proven and safe therapies commonly recommended and prescribed for secondary prevention.
Yes, clinical trial has been done with PolycapTM in Secondary prevention of CVD. TIPS 2 study was conducted in 518 patients with established vascular disease and BP≥130/80. Patients studied in TIPS 2 study had multiple risk factors and stable CVD.
TIPS 2 PolycapTM was found efficacious and safe in following group of patients with established vascular disease.
TIPS 2 study found that PolycapTM can control BP and Lipids in patients with established Vascular Disease and reduces the risk of CHD and stroke and is well tolerated.
TIPS 3 trial (Results published in the NEJM) evaluated the effects of Polycap in the primary prevention of cardiovascular disease and showed that Polycap with Aspirin reduced CVD by 31%, and Polycap alone reduced CVD by 21%.
- PolycapTM dose is 1-2 capsules once a day for CVD patients for Secondary Prevention.
- PolycapTM dose is 1 capsule once a day for Primary Prevention in patients at risk of CV events and stroke.
- PolycapTM is a Low Dose Combination Drug.
- Drug titration with additional therapies can be done along with PolycapTM.
- PolycapTM offers 5 proven and safe drugs recommended for Secondary Prevention in low dose. If a clinician needs to add additional dose for Residual Risk Management, it can be done based on patients blood pressure and lipid profile.
- Therefore, PolycapTM is not a hindrance for dose titration.
- Dose of PolycapTM is once a day preferably morning time.
- HCTZ in the morning
- Netherlands study showed that time does not matter!
- Take any fixed time.
- 1 OD in Primary Prevention
- 2 OD or 1 OD in Secondary Prevention
Can PolycapTM be used in Type 2 Diabetes patients?
- Therefore, PolycapTM is not a hindrance for dose titration.
- If the BP is not controlled by PolycapTM then increasing any one anti hypertensive drug or addition of another anti-hypertensive can be done.
- We could give additionally higher dose of Simvastatin or any other (non-statin) lipid lowering drug such as fibrate or ezetimibe or Niacin.
- No since PolycapTM contains aspirin it cannot be used in Hemorrhagic stroke patients.
- Yes it can be given in asthmatic patients, because at lower doses Atenolol does not loose its selectivity. At higher doses Atenolol (100mg) does lose its selectivity for β receptors and behaves like a non selective molecule.